Dr. Lutz Wevelsiep has more than 25 years of experience in international regulatory affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through marketing as well as particular expertise in anti-infectives. Lutz has prepared and managed interactions with all health authorities including the FDA, EMA, and EU national agencies.
Prior to joining UNION, Lutz spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes the successful European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®).
Lutz holds a Ph.D. and Postdoc in Chemistry from the Max-Planck Institute in Germany.
